Le Lézard
Classified in: Health, Science and technology

Bridget Gauer, Joins Cognosante as Senior Vice President of Strategy


SPRINGFIELD, Va., July 6, 2020 /PRNewswire-PRWeb/ -- Cognosante today announced the appointment of Bridget Gauer as the company's Senior Vice President of Strategy.

Gauer joins Cognosante after spending several years at the National Institutes of Health (NIH) Information Technology Acquisition and Assessment Center (NITAAC) where she served as the Director. In this role, Gauer set the strategic vision for the NIH GWAC program, which consists of three contract vehicles: CIO-SP3, CIO-SP3 Small Business, and CIO-CS.

"This is a vital time for Cognosante, and the addition of this role positions the company to reach the next level of size and scope. Bridget is a proven leader with a strong track record in acquisition management at large federal agencies, including the NIH and Department of Health and Human Services. She will be an excellent addition to our leadership team as she supports the company's overall growth process from pursuit to execution," says Michele Kang, Founder and Chief Executive Officer.

Gauer has over 25 years of acquisition and leadership expertise. Prior to joining NITAAC, she served as the Division Director of Contracts for the Health and Human Services (HHS) Assistant Secretary of Preparedness and Response and the Acting Director for the Acquisition Program Support Division with the Office of Acquisition Management, Contracts, and Grants Office. She has worked in several leadership positions within the Federal Acquisition community including with the Federal Communication Commission and the Department of Homeland Security. Gauer holds a B.S. in Recreation, an MBA, and an M.A. in National Security and Strategic Studies from the Naval War College.

"I am incredibly excited to join Cognosante. This role provides an opportunity for me to apply my government and leadership experience in a new capacity while focusing on strategy and growth. Together with my colleagues, I look forward to supporting Cognosante's mission and enhancing their relationships with additional government agencies," quoted Gauer.

About Cognosante
Cognosante provides technology solutions and business process outsourcing to Federal, state, and local government health agencies as well as social services and defense agencies. The company has more than a decade of experience working with States and the Federal government, developing, managing, and executing large, complex health information programs. Its expertise includes Medicaid, Medicare, military and Veterans' health, the health insurance marketplace, data standards and analytics, cybersecurity, biometrics, and modular system development and integration.

Visit cognosante.com for more information.

 

SOURCE Cognosante


These press releases may also interest you

at 22:00
The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.64 billion (USD 10.8 million1) in four projects for the development of new drugs for malaria and neglected tropical diseases (NTDs).2  The...

at 21:00
Renova Therapeutics, a biotechnology company developing gene therapy-based treatments for cardiovascular and metabolic diseases, announced today that it has focused its development and commercialization efforts for its RT-100 and RT-200 gene...

at 20:05
Organovo Holdings, Inc. ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration of clinical promise in three-dimensional (3D) human tissues, today announced the...

at 20:00
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology...

at 19:30
NCPDP announced today highlights from its 2024 Annual Technology & Business Conference, Innovation Starts Here. "NCPDP's standards and guidance are inherently innovative, and the work we continue to do will expand interoperability to support the...

at 19:25
Edwards Lifesciences today announced the European launch of the SAPIEN 3 Ultra RESILIA valve, the only transcatheter aortic heart valve to incorporate the company's breakthrough RESILIA tissue technology, designed to extend the valve's durability.*...



News published on and distributed by: